Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

642.55INR
28 Apr 2017
Change (% chg)

Rs5.60 (+0.88%)
Prev Close
Rs636.95
Open
Rs644.95
Day's High
Rs644.95
Day's Low
Rs638.30
Volume
321,776
Avg. Vol
361,540
52-wk High
Rs854.50
52-wk Low
Rs572.40

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.29
Market Cap(Mil.): Rs1,542,264.00
Shares Outstanding(Mil.): 2,399.29
Dividend: 1.00
Yield (%): 0.16

Financials

  SUN.BO Industry Sector
P/E (TTM): 20.81 29.41 30.38
EPS (TTM): 30.89 -- --
ROI: -- 13.85 13.36
ROE: -- 14.79 14.50

BRIEF-Sun Pharma says filing of tildrakizumab with European Medicines Agency by Almirall

* Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall.

24 Mar 2017

BRIEF-Sun Pharma Industries says Canadian unit to acquire Thallion Pharma

* Taro Pharmaceuticals Inc. (Canada) entered into deal to acquire all issued and outstanding shares of Thallion Pharma

17 Mar 2017

India's Sun Pharma says U.S. FDA to lift ban on Mohali plant exports

MUMBAI India's largest drugmaker Sun Pharmaceutical Industries said U.S. regulators plan to lift a ban on its Mohali plant in northern India, paving the way for a resumption of exports to the company's biggest market after four years.

14 Mar 2017

Sun Pharma says U.S. FDA to lift ban on Mohali plant exports

MUMBAI India's largest drugmaker Sun Pharmaceutical Industries said U.S. regulators plan to lift a ban on its Mohali plant in northern India, paving the way for a resumption of exports to the company's biggest market after four years.

14 Mar 2017

UPDATE 1-India's Sun Pharma says U.S. FDA to lift ban on Mohali plant exports

* Mohali was one of the plants Sun gained through Ranbaxy deal

14 Mar 2017

India's Sun Pharma says FDA to lift ban on Mohali drug plant

MUMBAI, March 14 India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday that U.S. regulators plan to lift a ban on its Mohali plant in northern India, allowing the company to restart supplies from there after four years.

14 Mar 2017

BRIEF-Sun Pharmaceutical Industries says USFDA will lift import alert on Mohali manufacturing facility

* Says USFDA will lift the import alert imposed on the Mohali (Punjab) manufacturing facility

14 Mar 2017

Indian shares reverse gains as investors book profit

March 2 Indian shares retreated from near two-year highs to end lower on Thursday as investors booked profit in pharmaceutical and realty stocks such as Sun Pharmaceutical Industries and DLF Ltd.

02 Mar 2017

BRIEF-Sun Pharmaceutical Industries says European Medicines Agency approves Tobramycin

* Sun Pharmaceutical Industries clarifies on news item "UK regulator approves Sun Pharma generic drug of Tobramycin"

16 Feb 2017

MEDIA-Sun Pharma's Halol facility to stop making key drugs - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

16 Feb 2017

More From Around the Web

Earnings vs. Estimates